[go: up one dir, main page]

EP1404318A2 - Composes et procedes permettant de reguler la differentiation cellulaire - Google Patents

Composes et procedes permettant de reguler la differentiation cellulaire

Info

Publication number
EP1404318A2
EP1404318A2 EP01998033A EP01998033A EP1404318A2 EP 1404318 A2 EP1404318 A2 EP 1404318A2 EP 01998033 A EP01998033 A EP 01998033A EP 01998033 A EP01998033 A EP 01998033A EP 1404318 A2 EP1404318 A2 EP 1404318A2
Authority
EP
European Patent Office
Prior art keywords
cell
sep
cells
occurrence
regulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01998033A
Other languages
German (de)
English (en)
Inventor
Kenneth H. Falchuk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/977,866 external-priority patent/US6908732B2/en
Application filed by Harvard University filed Critical Harvard University
Publication of EP1404318A2 publication Critical patent/EP1404318A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des procédés et des réactifs permettant d'inhiber la croissance cellulaire ou de favoriser la différentiation cellulaire. Ces procédés consistent à mettre en contact la cellule avec une différéguline en quantité suffisante pour inhiber la prolifération cellulaire ou pour favoriser la différentiation cellulaire.
EP01998033A 2000-11-10 2001-11-13 Composes et procedes permettant de reguler la differentiation cellulaire Withdrawn EP1404318A2 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US977866 1997-11-25
US24729900P 2000-11-10 2000-11-10
US247299P 2000-11-10
US26223301P 2001-01-17 2001-01-17
US262233P 2001-01-17
US26481401P 2001-01-29 2001-01-29
US264814P 2001-01-29
US09/977,866 US6908732B2 (en) 2000-10-13 2001-10-15 Compounds and methods for regulating cell differentiation
PCT/US2001/047309 WO2002055075A2 (fr) 2000-11-10 2001-11-13 Composes et procedes permettant de reguler la differentiation cellulaire

Publications (1)

Publication Number Publication Date
EP1404318A2 true EP1404318A2 (fr) 2004-04-07

Family

ID=27500253

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01998033A Withdrawn EP1404318A2 (fr) 2000-11-10 2001-11-13 Composes et procedes permettant de reguler la differentiation cellulaire

Country Status (3)

Country Link
EP (1) EP1404318A2 (fr)
AU (1) AU2002249795A1 (fr)
WO (1) WO2002055075A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101677992A (zh) 2006-11-13 2010-03-24 M·F·麦卡蒂 抑制nadph氧化酶活性的组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5381611A (en) * 1976-12-28 1978-07-19 Kimihiko Okazaki Hepatic medicine
JP2933229B2 (ja) * 1989-04-11 1999-08-09 日本ハム株式会社 エイズウイルスの増殖抑制剤
JPH06183969A (ja) * 1992-05-22 1994-07-05 Nippon Ham Kk 抗補体剤
CN1185956A (zh) * 1996-12-23 1998-07-01 周德 一种治疗癌症的药物
US7084126B1 (en) * 2000-05-01 2006-08-01 Healthpartners Research Foundation Methods and compositions for enhancing cellular function through protection of tissue components
CA2412623A1 (fr) * 2000-06-14 2001-12-20 Brian J. Day Tetrapyrroles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO02055075A2 *

Also Published As

Publication number Publication date
WO2002055075A2 (fr) 2002-07-18
WO2002055075A9 (fr) 2004-02-26
AU2002249795A1 (en) 2002-07-24
WO2002055075A3 (fr) 2003-12-31

Similar Documents

Publication Publication Date Title
US6902881B2 (en) Compounds and methods for regulating cell differentiation
Xu et al. 5-(3, 4-Difluorophenyl)-3-(6-methylpyridin-3-yl)-1, 2, 4-oxadiazole (DDO-7263), a novel Nrf2 activator targeting brain tissue, protects against MPTP-induced subacute Parkinson's disease in mice by inhibiting the NLRP3 inflammasome and protects PC12 cells against oxidative stress
CA2587489C (fr) Mediateurs de chemins de signalisation hedgehog, compositions et utilisations liees a ceux-ci
US6686388B2 (en) Regulators of the hedgehog pathway, compositions and uses related thereto
US7655674B2 (en) Modulators of hedgehog signaling pathways, compositions and uses related thereto
AU768130B2 (en) Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
US20120183603A1 (en) Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
JP2003516317A (ja) ヘッジホッグ経路の調節物質、並びにそれに関する組成物及び利用法
WO2005033048A2 (fr) Antagonistes de voie wnt
Zheng et al. Latanoprost promotes neurite outgrowth in differentiated RGC-5 cells via the PI3K-Akt-mTOR signaling pathway
RU2492866C2 (ru) Способы созревания фолликулов яичника in vitro
WO2010148094A1 (fr) Procédés et compositions pour augmenter la puissance trichogène de cellules dermiques
EP1404318A2 (fr) Composes et procedes permettant de reguler la differentiation cellulaire
US6908732B2 (en) Compounds and methods for regulating cell differentiation
UA79753C2 (en) Mediators of hedgehog signaling pathways, compositions and uses related thereto
AU2005201269B2 (en) Regulators of the PCT or smoothened pathway, compositions and uses related thereto
JP2004531458A (ja) ヘッジホッグシグナル伝達経路メディエーター、それに関連した組成物及び利用

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030509

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20040401

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040812